Doug Sandler, of the Riverfront Investment Group, thinks biotech is set to go higher after earnings season and could be an investor’s chance to play catch-up. Doug draws a correlation between biotech and the technology sector. With the recent run in Technology, Doug thinks that biotech has lagged behind, and has room to catch up. Doug warns that in the biotech sector, there is a tendency to be either a blow up or a home run, with blow ups more of the norm. He thinks that ETF’s are the way to play the potential growth, as you are given diversification to many different companies.

See his interview with CNBC below:

GET A FREE TREND ANALYSIS  FOR ANY ETF HERE!

---

Related posts:

1. Emerging-Market ETFs Hit Historic Lows: Don’t Miss Your Chance To Load Up (EEM, ECH, EWY, EWS, HILO)
2. Fixed Income ETFs and Yield: A Game of Catch Up
3. Who would turn down a chance to buy into emerging markets at a 75-percent discount?
4. Is A Return To The Gold Standard On The Horizon? Not A Chance (GLD, GDX, GDXJ, DZZ, UUP)

IBB, NYSE:BBH, NYSE:FBT, PBE, XBI